| Formulary Chapter 6: Endocrine system - Full Section
|
Notes:
This chapter is mostly updated. The section still outstanding is 6.4.1.1 (oestrogens and HRT).
|
| Useful Links |
 Guideline for antidiabetics therapy for type 2 diabetes (March 2021) |
|
Guidelines for the use of blood glucose meters, test strips and lancets in diabetes (March 2020) |
|
BSSE APC Risk assessment- High strength insulins/ Biosimilars/ Fixed combination |
 Gender dysphoria: Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy for Transgender and Non-Binary Adults (updated) |
|
Insulin Guidelines for Adults and Children with Type 1 and Type 2 Diabetes Mellitus V 1.0 |
|
Insulin pen needles (June 2018) |
|
Primary Care Sick Day Guidance for the management of adult patients with diabetes mellitus |
|
Treatment and Management of Hypoglycaemia in Adults with Diabetes Mellitus |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
06.01 |
Drugs used in diabetes (0,0)
|
|
06.01.01 |
Insulins (0,0)
|
|
06.01.01.01 |
Short-acting insulins
(7,7)
|
|
06.01.01.02 |
Intermediate- and long-acting insulins
(10,7)
|
|
|
Biphasic insulins
(4,1)
|
|
06.01.02 |
Antidiabetic drugs (0,0)
|
|
06.01.02.01 |
Sulphonyureas
(3,5)
|
|
06.01.02.02 |
Biguanides
(3,1)
|
|
06.01.02.03 |
Other antidiabetic drugs
(0,13)
|
|
|
DPP-4 inhibitors (0,0)
|
|
|
Alpha glucosidase inhibitors (0,0)
|
|
|
GLP-1 mimetics (0,0)
|
|
|
DPP4 inhibitors (gliptins)
(3,0)
|
|
|
SGLT2 inhibitors
(5,0)
|
|
|
GLP1 agonists
(4,3)
|
|
|
Meglitinides
(1,0)
|
|
|
SGL2 inhibitors (0,0)
|
|
|
Other (0,0)
|
|
|
Thiazolidinediones
(1,0)
|
|
|
Glucagon-like peptide-1 receptor agonists - once weekly (0,0)
|
|
06.01.02.07 |
Other antidiabetic drugs (0,0)
|
|
06.01.03 |
Diabetic ketoacidosis (0,0)
|
|
06.01.04 |
Treatment of hypoglycaemia
(3,0)
|
|
|
Chronic hypoglycaemia
(0,1)
|
|
06.01.05 |
Treatment of diabetic nephropathy and neuropathy (0,0)
|
|
|
Diabetic nephropathy (0,0)
|
|
|
Diabetic neuropathy (0,0)
|
|
06.01.06 |
Diagnostic and monitoring agents for diabetes mellitus
(1,0)
|
|
|
Blood glucose monitoring
(1,0)
|
|
|
Urinalysis
(0,20)
|
|
|
Oral glucose tolerance test (0,0)
|
|
06.02 |
Thyroid and Antithyroid drugs (0,0)
|
|
06.02.01 |
Thyroid hormones
(2,1)
|
|
06.02.02 |
Antithyroid drugs
(3,0)
|
|
06.03 |
Corticosteroids (0,0)
|
|
06.03.01 |
Replacement therapy
(1,0)
|
|
06.03.02 |
Glucocorticoid therapy
(10,5)
|
|
|
Disadvantages of corticosteroids (0,0)
|
|
|
Use of corticosteroids (0,0)
|
|
|
Pregnancy and breastfeeding (0,0)
|
|
|
Administration (0,0)
|
|
|
Withdrawal of corticosteroids (0,0)
|
|
06.04 |
Sex hormones (0,0)
|
|
06.04.01 |
Female sex hormones and their modulators
(0,1)
|
|
06.04.01.01 |
Oestrogens and HRT
(31,15)
|
|
|
Hormone replacement therapy (0,0)
|
|
|
Ethinylestradiol
(1,0)
|
|
|
Raloxifene
(1,0)
|
|
06.04.01.02 |
Progestogens
(5,4)
|
|
06.04.02 |
Male sex hormones and antagonists
(5,7)
|
|
|
Anti-androgens
(4,0)
|
|
06.04.03 |
Anabolic steroids
(2,0)
|
|
06.04.04 |
Gender dysphoria (0,0)
|
|
06.05 |
Hypothalamic and pituitary hormones and anti-oestrogens
(0,1)
|
|
06.05.01 |
Hypothalamic and anterior pituitary hormones and anti-oestrogens (0,0)
|
|
|
Anti-oestrogens
(1,0)
|
|
|
Anterior pituitary hormones
(5,7)
|
|
|
Hypothalmic hormones
(1,2)
|
|
06.05.02 |
Posterior pituitary hormones and antagonists (0,0)
|
|
|
Posterior pituitary hormones
(1,3)
|
|
|
Antidiuretic hormone antagonists
(3,0)
|
|
06.06 |
Drugs affecting bone metabolism (0,0)
|
|
|
Osteoporosis (0,0)
|
|
06.06.01 |
Calcitonin and parathyroid hormone
(3,0)
|
|
06.06.02 |
Bisphosphonates and other drugs affecting bone metabolism (0,0)
|
|
|
Bisphosphonates
(9,3)
|
|
|
Denosumab
(2,0)
|
|
|
Strontium renelate
(0,1)
|
|
06.07 |
Other endocrine drugs (0,0)
|
|
06.07.01 |
Bromocriptine and other dopaminergic drugs
(3,0)
|
|
06.07.02 |
Drugs affecting gonadotrophins
(2,2)
|
|
|
Gonadorelin analogues
(6,1)
|
|
|
Breast pain (mastalgia) (0,0)
|
|
06.07.03 |
Metyrapone
(1,1)
|
|
06.07.04 |
Somatomedins
(1,0)
|
